Chronic myelogenous leukemia (CML) is a hematopoietic disorder originating from p210BCR/ABL-transformed stem cells, which begins as indolent chronic phase (CP) but inevitably progresses into fatal blast crisis (BC). To investigate molecular mechanism(s) underlying disease evolution, CML-exhibiting p210BCR/ABL transgenic mice were subjected to retroviral insertional mutagenesis, by being crossed with BXH2 mice that transmit a replication-competent retrovirus. In contrast that non-transgenic mice in the 
Introduction
Chronic myelogenous leukemia (CML) is a hematopoietic disorder of multipotential stem cells, which exhibits excessive proliferation of immature and mature myeloid cells. 1, 2 The cytogenetic hallmark of CML is the Ph chromosome, created by t(9;22)(q34;q11), 3 where the amino-terminal BCR gene on chromosome 22 is fused to most of the ABL proto-oncogene on chromosome 9, thereby creating an 8.5 kb BCR/ABL chimeric mRNA encoding a 210KD hybrid protein (p210BCR/ABL). [4] [5] [6] p210BCR/ABL possesses a much higher kinase activity in comparison to the normal 145kDa c-ABL, 7 which is believed to play a critical role in the pathogenesis of the disease.
The clinical course of CML is characterized by hematologically and temporally distinct stages. 1, 2 In the initial stage, called chronic phase (CP), the disease is indolent and the leukemic cells retain an ability to differentiate into mature granulocytes. After several years' duration of the chronic phase, however, the disease inevitably accelerates and ultimately progresses to the terminal fatal stage, called blast crisis (BC), which involves aggressive proliferation of immature blast cells. The frequent appearances of additional chromosomal abnormalities in the blast phase strongly suggest that superimposed genetic events would account for the disease evolution, 8 but the underlying molecular mechanism(s) has remained largely unknown.
To understand the complex processes involved in the clinical course of human CML, it is necessary to develop animal models that express p210BCR/ABL and recapitulate the clinical features of the disease. Major attempts have been focused on bone marrow transplantation (BMT) experiments. Mice lethally irradiated and transplanted with bone marrow (BM) cells infected with p210BCR/ABL-expressing retroviruses exhibited a CML-like myeloproliferative disorder. [9] [10] [11] On the other hand, generation of transgenic mice expressing p210BCR/ABL under various promoters also provides useful models. [12] [13] [14] [15] [16] [17] We generated p210BCR/ABL transgenic mice using the promoter from the mouse TEC gene, a gene encoding protein-tyrosine kinase
For personal use only. on . by guest www.bloodjournal.org From 4 preferentially expressed in hematopoietic progenitor cells. 18, 19 While the founder mouse died of T-cell acute lymphoblastic leukemia (ALL) with a short latency, transgenic offspring reproducibly exhibited a myeloproliferative disorder after a long latency period. 14 Peripheral blood smear showed remarkable myeloid hyperplasia with maturation, the BM was hypercellular with a predominance of myeloid cells at various stages of differentiation, and the spleen was enlarged with proliferation and expansion of myeloid cells. 14 These pictures represent cardinal features of human CML, allowing us to consider these transgenic mice an animal model for CML.
To examine whether this transgenic model is applicable for investigating pathogenic processes from CP to BC of CML, we crossed p210BCR/ABL transgenic mice with mice heterozygous for p53, a gene frequently inactivated in CML BC, and generated mice transgenic for p210BCR/ABL and heterozygous for p53. 20 Interestingly, p210BCR/ABL transgenic, p53 heterozygous mice died of acute leukemia with a short latency, and the analysis of p53 status revealed that the residual normal p53 allele was frequently and preferentially lost in the tumor tissues. 20 In addition, we crossed p210BCR/ABL transgenic mice with Dok-1/Dok-2 knockout mice and showed that the absence of Dok-1 and Dok-2 accelerated the disease phenotype and caused BC, defining the role of Dok-1 and Dok-2 in tumor suppression. 21 Based on these results, our transgenic mice can be regarded as a useful model for investigating molecular mechanism(s) underlying the progression from CP to BC of human CML.
In this report, to identify genes whose altered expression causes CML BC, p210BCR/ABL transgenic mice were subjected to retroviral insertional mutagenesis, by backcrossing to BXH2 mice, a recombinant inbred mouse strain that mainly develop myeloid leukemia due to a horizontally transmitted replication-competent retrovirus and intrinsic myeloid tropism induced by a mutation in the Icsbp1/Irf8 locus.
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Materials and Methods

Mice
p210BCR/ABL transgenic mice were generated as described.
14 To allow for retroviral insertional mutagenesis, p210BCR/ABL transgenic males were backcrossed 4 generations to BXH2 females, since the ecotropic retrovirus in the BXH2 strain is transmitted to the progeny through the milk. Genotyping of the mice was carried out as described. 14 All the mice used in this study were kept according to the guidelines of the Institute of Laboratory Animal Science, Hiroshima University and all murine studies were approved by the animal care committee at the Japanese Foundation for Cancer
Research.
Hematological and pathological analyses
Peripheral blood counts were routinely examined. Smears and stamp specimens of leukemic tissues were stained with Wright-Giemsa (WG). Tissues from dead or moribund animals were fixed in 10% buffered formaldehyde and examined by light microscopy. All organs were examined grossly and representative slices were prepared for hematoxylin-eosin staining.
Southern and northern blot analyses
To detect gene rearrangements, genomic DNAs were digested with appropriate restriction enzymes and blotted with a genomic fragment adjacent to the integration site.
For transgene promoter, a BglI-SmaI fragment in the promoter region was used as a probe, and for Zfp423, a genomic fragment generated by PCR (primer sequences are 5′-GTGCGCACGTTTGTGAGGAGCTATA-3′ and 5′-CCAGCTATTCTGTCCAGGAGCAAGA-3′), which corresponds to a part of the 1st intron, was used as a probe. To detect RNA expression, total RNA extracted using TRIzol (Invitrogen, California, CA) or mRNA purified using Oligo-Tex (Takara Bio Inc, Tokyo, Japan) was blotted with p210BCR/ABL cDNA, Zfp423 cDNA, or a part of coding region of ZNF423 cDNA generated by genomic PCR (primer sequences are 5′-CAACCAGAAACACAAGTGCCCCATG-3′ and 5′-GTTGCAGTGGAAGGCAGAGATGTTG-3′).
RT-PCR
RNA was extracted as described above. RT-PCR was performed as described (primer sequences are 5′-GAATGTCATCGTCCACTCAGCC-3′ and 5′-GGCCACAAAATCATACAGTGCA-3′ for p210BCR/ABL, 5′-GAGGATACCCCTACGACGTG-3′ and 5′-GACTTGTCACGCTGTTCCTGTC-3′ for Zfp423, and 5′-GGCATCAACCACGAGTGTAAGC-3′ and 5′-CTTCTGCGGAGAGGTGTCCTGT-3′ for ZNF423).
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Western blot analysis
Proteins extraction and Western blot were performed as described.
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Flow cytometric analysis
Cells were stained with monoclonal antibodies and second reagents. FITC-, PE-, and biotin-labeled monoclonal antibodies were purchased from BD PharMingen (San Diego, CA) (Thy-1.2, CD19, CD45R/B220, Mac-1, Gr-1, and CD3) or from eBiosciences (San Diego, CA) (CD43, IgM, BP-1, and CD20 
Identification of retroviral integration sites
Genomic DNAs were digested with restriction enzymes, self-ligated, and subjected to inverse PCR as described, 22 except that the CUA and CAU repeats were deleted from the secondary PCR primers. The position mapping on the mouse chromosome was done by BLAST searching using the UCSC Genome Bioinformatics database (http://genome.ucsc.edu/) and the definition of a common integration site (CIS) was the same as in the mouse retrovirus tagged cancer gene database (RTCGD) (http://rtcgd.abcc.ncifcrf.gov/).
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Retrovirus-mediated gene transfer, colony formation assay, and bone marrow transplantation Retroviral preparation and retrovirus-mediated gene transfer were performed as described. 26 For colony assay, BM cells of 5FU-treated transgenic or non-transgenic littermates were cultured in αMEM+20% FCS supplemented with 10 ng/ml IL-6, 10 ng/ml IL-3, and 100 ng/ml SCF (R&D Systems, Minneapolis, MN). Retrovirus was generated using plat-E cells 27 and added into the medium containing BM cells with 6 mg/ml of Polybrene (Sigma, St Louis, MO), and retrovirus-infected BM cells were subjected for B-cell colony assay using MethoCult M3630 (StemCell Technologies Inc.
Vancouver, Canada) that contains rhIL7. After 7-12 days' incubation, green colony numbers were counted under a fluorescent microscope.
For BM transplantation, BM cells extracted from 5FU-untreated Balb/c mice were cultured 24 hours in IMDM+15% FCS supplemented with 10 ng/ml IL-6, 10 ng/ml IL-3, 100 ng/ml SCF and 10 ng/ml of IL-7 (R&D Systems, Minneapolis, MN). Retrovirus infection and BM transplantation were performed as described.
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Retrovirus-mediated transduction of short hairpin RNA (shRNA) for ZNF423
Two shRNA target sequences for ZNF423 (5′-GACATACCAGTGCATCAAG-3′ for Infected cells were selected with puromycin (0.4 mg/ml) for 2 weeks, subsequently cultured in puromycin-free medium for at least another 2 weeks, and subjected to northern blot and cell proliferation assay.
Cell proliferation assay
On day 1, 1×10 5 of cells of the parental and shRNA-transduced sublines were plated in a 10cm 2 dish and cultured in RPMI+10%FCS. Cell numbers were counted on day 3 and day 5.
Cell lines and patient samples
Ph-positive and Ph-negative human hematopoietic cell lines were kindly provided by 
Results
Acute leukemias in p210BCR/ABL transgenic mice on a BXH2 background
To identify gene(s) whose alteration by retrovirus insertion contributes to blast crisis of CML, p210BCR/ABL transgenic mice were backcrossed to BXH2 mice that contain and transmit a replication-competent retrovirus. p210BCR/ABL transgenic and wild-type (non-transgenic) littermates from the N4 BXH2 backcross generation were used for this study (designated as p210BCR/ABL/BXH2 and WT/BXH2, respectively).
WT/BXH2 began to develop acute leukemia at 6 months after birth ( Fig. 1 , all the samples were positive for CD20, B220, BP-1, and CD43 but negative for IgM, indicating that they were pre-B cell leukemias.
The characteristics of the six p210BCR/ABL/BXH2 leukemic mice with an early disease onset are summarized in Table 1 
Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423 in the leukemic tissues with B-cell phenotype
We focused on the six p210BCR/ABL/BXH2 mice that developed non-myeloid leukemias in a shortened period, since diseases in these mice would not be only due to the BXH2 background-derived intrinsic mechanism but caused by cooperation of p210BCR/ABL with retrovirus-inserted altered gene expression. To identify virus-affected genes in these mice, inverse PCR (iPCR) was performed and sequences of PCR fragments were subjected to BLAST searching using the UCSC Genome Bioinformatics database. Among candidate genes (listed in Supplemental gene. 31 In these cases, the retroviruses were integrated almost in the same position, ~100bp upstream of the translational initiation ATG. 31 The schematic models of the integration sites are shown in Fig. 2A .
To confirm that these CISs were major integration sites in the leukemic samples, Southern blot was performed using a genomic DNA fragment adjacent to the integration site. DNA extracted from a spleen of a BXH2-non-backcrossed p210BCR/ABL transgenic mouse was used as a negative control. As shown in were cultured in methylcellulose-based media (Fig. 3A) . Since mice with Zfp423
For 5A ). As expected, no difference in cell growth was observed in the parental line and shRNAs-transduced sublines (Supplemental Fig. 4) , confirming the specificity of the shRNAs on the ZNF423-dependent cell growth. These results indicated that contributes to the evolution to CML BC. 8 We developed a transgenic mouse model for human CML, which expresses p210BCR/ABL in hematopoietic progenitor cells and reproducibly exhibits a CML-like myeloproliferative disorder. 14 To investigate molecular mechanism(s) responsible for disease progression, the p210BCR/ABL transgenic mice were subjected to retroviral insertional mutagenesis. BXH2 mice which harbor a horizontally transmittable replication-competent retrovirus 22 was used as a virus donor strain, since it has been successfully used to detect second hit genes in previous studies.
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The inbred BXH2 mice were reported to develop acute myeloid leukemia at 7-12 months of age due to ecotropic virus integration and intrinsic myeloid tropism. [22] [23] [24] In line with this report, all the WT/BXH2 mice died of myeloid leukemia (Fig. 1A) . In contrast, six p210BCR/ABL/BXH2 mice developed non-myeloid leukemias with a shorter latency. The early disease onset and different phenotypes in these mice indicated that the diseases were caused by the cooperation of p210BCR/ABL with altered expression of virus-affected gene(s). Therefore, in this study, we intended to identify virus-integrated genes in the tumors of the six mice and iPCR analysis detected two CISs in B-cell leukemia samples. These CISs were considered to be strong candidates for CML BC, since leukemia with B-cell phenotype has not been detected in p210BCR/ABL transgenic mice 14 and very rarely reported in BXH2 mice (http://rtcgd.abcc.ncifcrf.gov/). 22, 23 It is to be noted that one CIS was in the promoter region of the transgene.
Interestingly, our previous retrovirus insertional mutagenesis study, in which newborn p210BCR/ABL transgenic mice were directly injected with retroviruses, also identified the transgene as a CIS in B-cell BC cases, where retrovirus integration resulted in Another CIS was the 5′ non-coding region of Zfp423, which encodes a transcription factor with multiple zinc-finger repeats. 31 Zfp423 was originally identified as a binding partner of Ebf (early B-cell factor, also denoted as Olf1), a protein essential for B-cell and olfactory nervous system development, 41, 42 and was subsequently shown to interact with SMADs in response to bone morphogenic protein 2 (BMP2) in the Xenopus laevis.
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Zfp423 was also cloned as a target in B-cell lymphoma in AKXD27 mice by retroviral insertional mutagenesis. 31 In that study, retrovirus integration occurred upstream of the translation initiation codon resulting in a high level of expression, as observed in our cases (Fig. 2) . 31 A recent study demonstrated that Zfp423 knockout mice exhibited abnormal cerebellum development but appeared to have a normal hematopoiesis, 44 suggesting that its ectopic expression would be involved in leukemogenesis.
It remains to be clarified how overexpression of Zfp423 contributes to B-cell malignancy. Interestingly, although Zfp423 was originally identified as an Ebf-binding partner, it is not expressed in hematopoietic tissues including B-cells. 31, 32 In the olfactory nervous system, Zfp423 was shown to negatively regulate Ebf function;
Zfp423 forms a heterodimer with Ebf, which inhibits Ebf homodimer formation that has (Fig. 3) . In addition, expression of Zfp423 with p210BCR/ABL in hematopoietic progenitor cells accelerated p210BCR/ABL-mediated leukemia and induced a more aggressive phenotype mainly of B-cell lineage (Fig. 4) . It is intriguing that while the recipient mice transduced with both p210BCR/ABL and Zfp423 mainly developed B-ALL, two cases developed AML (Fig. 4B) . Although 31, 32 this result strongly suggests that Zfp423 might contain a potency to develop AML as well as B-ALL. This idea is in accordance with the finding that one myeloid BC case expressed ZNF423 in clinical analysis (No. 6 in Fig. 5B ).
Zfp423 has been exclusively associated with B-ALL in retroviral insertional
Recently, Zfp521/ZNF521 (also known as EHZF (early hematopoietic zinc finger protein) and Evi3), which is homologous to Zfp423/ZNF423 and was also identified as a target of B-ALLs by mouse retrovirus insertional mutagenesis studies, 32, 46 was reported to be frequently involved in AML samples in human leukemias. 47 Thus, a set of zinc finger-containing transcription factors that have been isolated as a target in B-ALL in mice might contribute to leukemias with different phenotypes in humans.
As for the two mice that developed T-ALL, although we could not identify any CIS, 52 and Sox4 was demonstrated to be a powerful tool to identify cooperative genes when transplanted by a replication-defective retrovirus. 53 Further studies will be required to investigate whether virus insertion in these genes might affect the BC phenotype and/or lineage commitment observed in p210BCR/ABL/BXH2 mice.
In this study, we demonstrated that enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 contribute to blastic transformation of 
